Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia.
Cancer Treat Rev
; 69: 224-232, 2018 Sep.
Article
en En
| MEDLINE
| ID: mdl-30098484
ABSTRACT
BACKGROUND:
Acute myeloid leukemia (AML) is a rare hematologic malignancy largely affecting older adults. Comorbidities may compromise fitness and eligibility for high-intensity chemotherapy (HIC). This study presents the results of two systematic reviews (SRs) assessing (1) the impact of AML and current treatments on health-related quality of life (HRQoL), and (2) the economic burden and cost drivers of AML in patients who are ineligible for HIC.METHODS:
Electronic searches (MEDLINE, EMBASE, EconLit, Cochrane library) were supplemented with manual searching of conference, utility, and HTA databases. All studies reporting HRQoL or economic data for patients with AML who were ineligible for HIC were included.RESULTS:
The HRQoL SR included ten studies. Patients with AML have lower baseline HRQoL than other cancer patients or the general population, and those receiving lower intensity treatment have lower HRQoL than those eligible for HIC. Low baseline HRQoL predicts poor outcomes, and treatment had variable effects on HRQoL. The economic burden SR included nine studies. Medical costs varied widely, reflecting the heterogeneity of AML. Hospitalization is a key cost driver in AML treatment but was largely not considered in cost studies. Medical resource utilization comprised drug acquisition, drug administration, disease monitoring tests, transfusions, adverse event management, supportive care/monitoring costs and terminal care.CONCLUSION:
As new drugs emerge that extend survival, assessment of HRQoL will be important to evaluate the quality of that survival. Cost data, driven by transfusions and hospitalization, will be important to evaluate the economic value of new treatments.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Leucemia Mieloide Aguda
Tipo de estudio:
Diagnostic_studies
/
Guideline
/
Health_economic_evaluation
/
Health_technology_assessment
/
Prognostic_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Cancer Treat Rev
Año:
2018
Tipo del documento:
Article